接种疫苗
爆发
医学
免疫
人口
2019年冠状病毒病(COVID-19)
内科学
病毒学
免疫学
疾病
环境卫生
免疫系统
传染病(医学专业)
作者
Zhigang Zheng,Yefeng Lu,Huimin Wu,Pui U. Lam,Xiaowei Sun,Yanyan Song,Hao Ji,Yi Luo,Tao Zhou,Mingxuan Feng,Ping Wan,Jianjun Zhu,Peiying Li,Jun Deng,Nan Shen,Qing Cao,Ji Liang,Qiang Xia,Feng Xue
标识
DOI:10.1186/s12985-024-02531-7
摘要
OBJECTIVES: Our study aims to explore the clinical characteristics of Omicron infection in pediatric liver transplant recipients (PLTRs), after the national COVID-19 outbreak. Additionally, we will investigate changes in vaccine coverage and parental attitudes towards vaccinating their children after this current outbreak. METHODS: We conducted a web-based questionnaire survey to gather information on Omicron infection, vaccination status, and guardian attitude among PLTRs. Besides, utilized valid questionnaire and long-term follow-up information processing techniques, and performed statistical analysis of relevant parameters. RESULTS: 528 valid questionnaires were collected, among which, 251 responses replied Omicron infection status. The Omicron infection rate in Chinese PLTRs was 56.2% (141/251), similar to the report in the normal population (around 60%). 99.3% of infected PLTRs presented mild symptoms, mostly with fever (78.0%), followed by Cough (76.6%), with a mean RTPCR conversion time of 7 days; the overall PLTRs' vaccination rate in this study was 13.3%, similar to that of our previous study (9.4%). Besides, we found no significant differences of either infection rate or clinical symptoms between the vaccinated and unvaccinated groups. Moreover, the study showed 61.6% of guardians supported COVID-19 inoculation despite the outbreak of Omicron status. CONCLUSIONS: The symptoms of Omicron infection in Chinese PLTRs were relatively mild, vaccine immunization had a limited effect on PLTRs' defense against Omicron infection, besides, their guardians supported the inoculation policy with a caution. CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn , identifier ChiCTR2200055968.
科研通智能强力驱动
Strongly Powered by AbleSci AI